Share This Page
Drug Price Trends for ADALIMUMAB-ADAZ(CF) PEN
✉ Email this page to a colleague
Average Pharmacy Cost for ADALIMUMAB-ADAZ(CF) PEN
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML | 61314-0327-20 | 1590.10591 | ML | 2026-05-20 |
| ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML | 61314-0327-20 | 1592.15654 | ML | 2026-04-22 |
| ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML | 61314-0327-20 | 1593.31786 | ML | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Overview of ADALIMUMAB-ADAZ(CF) PEN
Adalimumab-Adaz (CF) Pen is a biosimilar version of Humira (adalimumab), a monoclonal antibody targeting TNF-alpha. It treats rheumatoid arthritis, psoriasis, Crohn’s disease, and other autoimmune disorders. The key distinguishing feature is its administration via prefilled pen, offering ease of use and improved patient compliance.
As a biosimilar, ADALIMUMAB-ADAZ(CF) competes directly with the originator, Humira, which consistently ranks among top-selling drugs globally. Its market entry impacts pricing strategies and formulary positioning across regions.
Market Size and Penetration Potential
The global adalimumab market was valued at approximately $27.4 billion in 2022, with Humira accounting for over $20 billion of that revenue. Biosimilars launched in regions like Europe and the US have reduced prices and increased access.
Forecasts suggest the biosimilar segment will grow by a CAGR of 14-17% from 2023 to 2030, driven by patent expirations, healthcare cost containment policies, and increasing adoption in developing markets.
Analogous biosimilars such as Amgen’s Amjevita and Samsung Bioepis’ Imraldi demonstrate market penetration speeds of 25-40% within two years of launch in mature markets.
Market Penetration Estimates for ADALIMUMAB-ADAZ(CF)
| Region | Market Share (2 Years Post-Launch) | Notes |
|---|---|---|
| United States | 15-25% | Due to formulary inclusion and physician acceptance |
| European Union | 20-30% | Key markets include Germany, UK, France |
| Japan | 10-15% | Slower adoption due to regulatory and reimbursement policies |
Price Projections and Cost Dynamics
Launch Prices and Discounts
Manufacturers of biosimilars typically price 15-30% below the originator. Humira's US list price in 2023 exceeds $6,000 per injection. Biosimilars like ADALIMUMAB-ADAZ(CF) are expected to launch at an initial price 20-25% lower than Humira, with subsequent reductions.
5-Year Price Trends
| Year | US List Price per Pen | EU Average Price per Pen | Notes |
|---|---|---|---|
| 2023 | $4,500 - $5,400 | €3,500 – €4,200 | Launch phase, discounts apply |
| 2024 | $4,200 - $5,000 | €3,300 – €4,000 | Volume discounts likely |
| 2025 | $4,000 - $4,800 | €3,200 – €3,800 | Continued price erosion |
Pricing Factors
- Regulatory policy: Reimbursement policies influence net prices.
- Market competition: Entry of multiple biosimilars may drive prices down to below $3,500 per pen within five years.
- Physician and patient preferences: Ease of use via Pen device increases uptake, stabilizing prices.
Competitive Landscape
The biosimilar market for adalimumab includes key players:
- Amgen (Amjevita)
- Sandoz (Hulio)
- Samsung Bioepis (Imraldi)
- Pfizer (Abrilada)
Pricing varies based on agreements with payers and regional market conditions.
Regulatory and Reimbursement Trends
- The US FDA approved adalimumab biosimilars since 2017, including multiple formulations.
- European EMA aligns with the biosimilar pathway launched in 2005, with increasing acceptance.
- Reimbursement policies increasingly favor biosimilars, incentivizing formulary inclusion.
Regulatory Approval Status
| Region | Approval Date | Notes |
|---|---|---|
| US | 2023 (anticipated) | Pending FDA approval for ADALIMUMAB-ADAZ(CF) |
| EU | 2022 | Approved as a biosimilar to Humira |
| Japan | 2024 (projected) | Regulatory review underway |
Key Takeaways
- ADALIMUMAB-ADAZ(CF) Pen enters a market with established demand and rising biosimilar adoption.
- Price projections indicate initial discounts of 20-25% compared to Humira, with further reductions as competition intensifies.
- Market penetration in major regions could reach 20-30% within two years, supported by formulary agreements and physician familiarity.
- Regional differences influence pricing and adoption timelines, with US and Europe leading in biosimilar uptake.
- Patent expirations and regulatory support are central to the market expansion strategy; biosimilar manufacturer success depends on pricing, access facilitation, and physician acceptance.
FAQs
1. How does the ADALIMUMAB-ADAZ(CF) Pen compare in price to Humira?
It is expected to launch at a 20-25% discount, with prices decreasing over time due to market competition and volume discounts.
2. What factors influence biosimilar market penetration?
Regulatory approval, payer policies, physician acceptance, patient preferences for device delivery, and formulary inclusion are critical.
3. Which regions are most likely to see early uptake?
Europe and the US lead due to established biosimilar pathways and larger patient populations.
4. How does the Pen device impact market adoption?
Ease of administration improves patient compliance, making it a preferred option over traditional injectable forms.
5. What is the forecast for biosimilar price erosion in this market?
Prices for biosimilars may decline by another 15-30% over five years, driven by additional entrants and negotiating power.
References
[1] EvaluatePharma, "Biologics Market Size & Forecast," 2022.
[2] IQVIA, "Global Biosimilars Outlook," 2023.
[3] FDA & EMA regulatory filings, 2022-2023.
More… ↓
